4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
PepGen Inc. (PEPG) operates in the Biotechnology industry and is headquartered in Boston, United States with about 59 employees. Its market capitalization is roughly $156 million. In the fiscal year ended 2025-12-31, PEPG reported $0M in revenue and ($90M) in net income.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($94M) | ($98M) | ($85M) | ($68M) | — |
| Net Income | ($90M) | ($90M) | ($79M) | ($69M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($19M) | ($20M) | ($19M) | ($24M) | ($31M) |
| Net Income | ($18M) | ($18M) | ($18M) | ($23M) | ($30M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $174M | $151M | $143M | $217M | — |
| Total Liabilities | $26M | $32M | $35M | $38M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PEPG viewer.
About TickerBase · Data methodology & sources